The Food and Drug Administration today released two draft guidance documents aimed at reducing the ability of brand drug makers to use the agency’s Risk Evaluation and Mitigation Strategy programs as a way to block timely generic drug entry. The first document provides guidance on the development of a shared system REMS and includes general principles and recommendations to assist sponsors with developing these programs. The second guidance document describes when and how the FDA will consider waiving the single, shared system requirement, and how generic applicants can request a waiver. “We believe that by making the process for developing a shared system REMS more efficient, we’ll discourage brand drug makers from using REMS as a way to block generic entry and help end some of the tactics that can delay access,” FDA Commissioner Scott Gottlieb, M.D., said. “We’re also going to be clearer about the circumstances when we’ll issue waivers to let the generic firms develop their own REMS program.” The draft guidance documents will be published in tomorrow’s Federal Register. FDA will accept comments for 60 days.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.